382 related articles for article (PubMed ID: 12055220)
1. Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity.
Stern BV; Boehm BO; Tary-Lehmann M
J Immunol; 2002 Jun; 168(12):6099-105. PubMed ID: 12055220
[TBL] [Abstract][Full Text] [Related]
2. Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice.
Rosset MB; Ballerini C; Gregoire S; Metharom P; Carnaud C; Aucouturier P
J Immunol; 2004 May; 172(9):5168-74. PubMed ID: 15100253
[TBL] [Abstract][Full Text] [Related]
3. Fas/Fas ligand pathway, apoptosis, and clonal anergy involved in systemic acetylcholine receptor T cell epitope tolerance.
Deng C; Goluszko E; Christadoss P
J Immunol; 2001 Mar; 166(5):3458-67. PubMed ID: 11207304
[TBL] [Abstract][Full Text] [Related]
4. IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity.
Deng C; Radu C; Diab A; Tsen MF; Hussain R; Cowdery JS; Racke MK; Thomas JA
J Immunol; 2003 Mar; 170(6):2833-42. PubMed ID: 12626533
[TBL] [Abstract][Full Text] [Related]
5. Single-cytokine-producing CD4 memory cells predominate in type 1 and type 2 immunity.
Karulin AY; Hesse MD; Tary-Lehmann M; Lehmann PV
J Immunol; 2000 Feb; 164(4):1862-72. PubMed ID: 10657635
[TBL] [Abstract][Full Text] [Related]
6. Encephalitogenicity of complete Freund's adjuvant relative to CpG is linked to induction of Th17 cells.
Tigno-Aranjuez JT; Jaini R; Tuohy VK; Lehmann PV; Tary-Lehmann M
J Immunol; 2009 Nov; 183(9):5654-61. PubMed ID: 19812193
[TBL] [Abstract][Full Text] [Related]
7. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
[TBL] [Abstract][Full Text] [Related]
8. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
9. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.
Cassataro J; Estein SM; Pasquevich KA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH
Infect Immun; 2005 Dec; 73(12):8079-88. PubMed ID: 16299302
[TBL] [Abstract][Full Text] [Related]
11. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells.
Hofstetter HH; Shive CL; Forsthuber TG
J Immunol; 2002 Jul; 169(1):117-25. PubMed ID: 12077236
[TBL] [Abstract][Full Text] [Related]
12. T cell-depleted splenocytes from mice pre-immunized with neuroantigen in incomplete Freund's adjuvant involved in protection from experimental autoimmune encephalomyelitis.
Zheng H; Zhang H; Liu F; Qi Y; Jiang H
Immunol Lett; 2014; 157(1-2):38-44. PubMed ID: 24220208
[TBL] [Abstract][Full Text] [Related]
13. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
14. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
15. Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate Toll-like receptor 9-dependent, but CD4+ T cell help-independent, priming of CD8+ T cells.
Schirmbeck R; Riedl P; Zurbriggen R; Akira S; Reimann J
J Immunol; 2003 Nov; 171(10):5198-207. PubMed ID: 14607920
[TBL] [Abstract][Full Text] [Related]
16. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity.
Dredge K; Marriott JB; Todryk SM; Muller GW; Chen R; Stirling DI; Dalgleish AG
J Immunol; 2002 May; 168(10):4914-9. PubMed ID: 11994441
[TBL] [Abstract][Full Text] [Related]
17. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
Soares MM; Mehta V; Finn OJ
J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
[TBL] [Abstract][Full Text] [Related]
18. Autoreactive T cells persist in rats protected against experimental autoimmune encephalomyelitis and can be activated through stimulation of innate immunity.
Conant SB; Swanborg RH
J Immunol; 2004 May; 172(9):5322-8. PubMed ID: 15100271
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response.
Yip HC; Karulin AY; Tary-Lehmann M; Hesse MD; Radeke H; Heeger PS; Trezza RP; Heinzel FP; Forsthuber T; Lehmann PV
J Immunol; 1999 Apr; 162(7):3942-9. PubMed ID: 10201913
[TBL] [Abstract][Full Text] [Related]
20. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide.
Miconnet I; Koenig S; Speiser D; Krieg A; Guillaume P; Cerottini JC; Romero P
J Immunol; 2002 Feb; 168(3):1212-8. PubMed ID: 11801657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
